



Heidelberg, 16 April 2018
No. 41/2018

Cleavage Product of Alzheimer's Key Protein APP Stimulates Nerve Cell Communication

Researchers discover receptor for the protein fragment APP α mediating its physiological function

A cleavage product of the Alzheimer's APP protein stimulates nerve cell communication and memory. The protein fragment, known as APP α , has neuroprotective properties and acts as a signal molecule on other nerve cells. But how does it influence brain functions? An international research team led by Prof. Dr Ulrike Müller of Heidelberg University has gained new insights into the molecular mechanism underlying its physiological functions. The researchers discovered a receptor for APP α , which paves the way for new treatment approaches for Alzheimer's.

Alzheimer's disease (AD) is triggered by insoluble protein aggregates that are found as extracellular deposits in the brain of patients suffering from AD. The main component is the β -amyloid peptide (A β), which damages and eventually kills the nerve cells. This small peptide is a cleavage product of a substantially larger precursor protein, the amyloid precursor protein (APP). Alzheimer's was long assumed to be caused mainly by the overproduction of the β -amyloid peptide. "New studies show, however, that APP α levels drop over the course of the disease. APP α functions as an antagonist to the damaging A β ," explains Prof. Müller. "In Alzheimer's, there is a misregulation in APP cleavage whereby too little APP α is produced."

To find out how the neuroprotective APP α affects brain functions, the soluble protein fragment APP α was introduced via viral "vectors" into the hippocampus of genetically modified mice. The hippocampus is a brain region that is considered as crucial for memory formation. The researchers were able to demonstrate that APP α increases the number of synaptic contacts between nerve cells. "This was associated with more efficient nerve cell communication and improved memory in learning tests," states Ulrike Müller, professor of functional genomics at the Institute for Pharmacy and Molecular Biotechnology of Heidelberg University.

Further electrophysiological experiments revealed that APP α acts as a signaling molecule on the synaptic contacts of certain nerve cells. These synaptic contacts use the neurotransmitter acetylcholine, which is one of the most important messenger molecules for transmitting signals between nerve cells. The protein fragment APP α enhances signal transmission by acetylcholine receptors and increases their natural receptivity. This is the first time that researchers have identified a receptor for APP α in an animal model. "This paves the way for new options in Alzheimer's research, such as increasing the amount of APP α in the brain," states Prof. Müller.

Original publication:

M.C. Richter, S. Ludewig, A. Winschel, T. Abel, C. Bold, L.R. Salzburger, S. Klein, K. Han, S. Weyer, A.K. Fritz, B. Laube, D.P. Wolfer, C.J. Buchholz, M. Korte and U.C. Müller: Distinct *in vivo* role of secreted APP ectodomain variants APPs α and APPs β in regulation of spine density, synaptic plasticity, and cognition. EMBO Journal e98335 (16 April 2018), doi: 10.15252/emj.201798335

Internet information:

Müller Research Group – www.ipmb.uni-heidelberg.de/bioinfo-fkt_gen/mueller

Contact:

Prof. Dr Ulrike Müller
Institute for Pharmacy and Molecular Biotechnology
Phone +49 06221 54-6717
u.mueller@urz.uni-hd.de